The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2016Effect of HDAC Inhibition in Models of Parkinson's Disease
Study Rationale:
Numerous publications have linked the family of epigenetic enzymes known as HDACs (histone deactylases) to the underlying pathology of Parkinson's. This study will test the efficacy of... -
Rapid Response Innovation Awards, 2007Everyday Action Impairment in People with Parkinson's Disease Dementia/Dementia with Lewy Bodies
Objective/Rationale:
Parkinson’s disease (PD) and Parkinson’s Disease Dementia/Dementia with Lewy Bodies (PDD/DLB) have been associated with cognitive deficits and everyday action impairment (EAI; e.g... -
Biomarkers, 2011Identifying Peripheral Inflammatory Markers for Parkinson's Disease with Dementia (PDD)
Objective/Rationale:
Patients with Parkinson’s disease (PD) are at a 5.9 times greater risk of developing dementia than the normal population. The identification of sensitive molecular and cellular... -
Rapid Response Innovation Awards, 2008Effects of noradrenergic or serotoninergic system lesions combined with NS lesions on rodent models of 'non-motor'-like symptoms
Objective/Rationale:
Parkinson’s disease is widely attributed to neuropathy of dopaminergic neurones in the nigrostriatal (NS) pathway. Degeneration of noradrenergic and serotonergic neurones in the... -
Research Grant, 2023Exploiting a Novel Mechanism for Gene Regulation to Develop Innovative, Targeted Therapies for Parkinson’s Disease
Study Rationale: Neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) are associated with a variety of disease-causing mutations and genetic variants. In addition...
-
Therapeutic Pipeline Program, 2016Highly Selective M1 Muscarinic Receptor Positive Allosteric Modulators for the Treatment of Parkinson's Dementia
Study Rationale:
Up to 80% of individuals with Parkinson’s develop Parkinson’s disease dementia (PDD), which is characterized by a progressive loss of memory and a decline...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.